Tirzepatide for Individuals With Comorbid Obesity and Methamphetamine Use Disorder
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Effect of tirzepatide on self-reported use of methamphetamine
研究概览
简要总结
This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.
详细描述
This study will enroll up to 45 individuals with moderate-to-severe methamphetamine use disorder who meet the FDA-approved weight-related indication for tirzepatide [as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 1) 30 kg/m2 or greater (obesity) or 2) 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease)].
Enrolled participants will receive weekly treatment with tirzepatide for a 32-week period that will be followed by 4-week-long observational follow-up. Participants of this study will be seen for weekly visits where they will complete clinical and/or laboratory assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be 18 to 65 years of age, inclusive.
- •Be able to provide informed consent and ask relevant questions.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Be willing to adhere to the study medication regimen
- •Meet DSM-5 criteria for moderate or severe methamphetamine use disorder.
- •Self-report methamphetamine use on 18 or more days in the 30-day period prior to written informed consent using the Timeline Followback (TLFB).
- •Have an initial body mass index (BMI) at screening of:
- •30 kg/m2 or greater (obesity)
- •27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease).
- •If biologically female and is or becomes sexually active with a biological male, must agree to use acceptable methods of contraception and have urine pregnancy testing during participation in the study, unless unable to get pregnant
- •a. Appropriate birth control methods include: i. Oral contraceptives, contraceptive patch, hormonal vaginal contraceptive ring (with restrictions related to dose change given the medication interactions between tirzepatide and oral contraceptives).
- •ii. Barrier (diaphragm or condom) iii. Contraceptive implant iv. Medroxyprogesterone acetate injection v. Intra-uterine device vi. Complete abstinence from sexual intercourse vii. Surgical sterilization
- •Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
排除标准
- •Current or recent use (within 3 months prior to consent) of other tirzepatide-containing products or any other GLP-1 receptor agonist
- •Current or recent use (within 30 days) of sulfonylureas, other concomitantly administered insulin secretagogue, or insulin
- •Current or recent use (within 3 months prior to consent) of other weight loss agents
- •Weight loss surgery within 12 months prior to consent
- •Current eating disorder per clinician evaluation
- •Personal or family history of Medullary Thyroid Carcinoma
- •History of Multiple Endocrine Neoplasia syndrome type 2
- •Known serious hypersensitivity (e.g., anaphylaxis, angioedema) to tirzepatide or any of the excipients in tirzepatide
- •History of angioedema or anaphylaxis with a GLP-1 receptor agonist
- •Current Stage 3 or higher Chronic Kidney Disease, defined as eGFR <60 at Screening
- •Current inadequately controlled diabetes, defined as HbA1c > 7.0 at Screening
- •History of diabetic retinopathy
- •Current pregnancy or lactation
- •Treatment with another investigational drug or intervention within the past one month (30 days prior to consent)
- •Have any condition for which study participation would not be in their best interest (e.g., cognitive impairment, unstable general medical condition, intoxication, active psychosis) or that could prevent, limit, or confound the protocol-specified assessments, in the opinion of the investigator or their designee.
- •Require immediate hospitalization for psychiatric disorder or suicidal risk as assessed by a licensed study clinician.
研究组 & 干预措施
Tirzepatide
Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period in accordance with FDA-prescribing label guidelines.
干预措施: Tirzepatide (Drug)
结局指标
主要结局
Effect of tirzepatide on self-reported use of methamphetamine
时间窗: 36 weeks
Self-reported use of methamphetamine will be assessed through Timeline Followback. The Timeline Followback procedure will be used to elicit the participant's self-reported use of illicit substances, including but not limited to stimulants, and polysubstance use starting at the Screening Visit and continuing throughout study participation. During the Screening Visit, this form will be used to assess illicit use of substances for the 30-day period prior to written consent. During the study, TLFB will be administered to document the participant's self-reported use of illicit substances, nicotine, and tobacco for each visit since the previous TLFB assessment. Participant's drug of choice will be asked and determined by study coordinator and recorded along with the TLFB assessment.
次要结局
- Changes in body mass index from baseline to the end of the 32-week treatment phase(32 weeks)
- Feasibility of using tirzepatide in individuals with Methamphetamine Use Disorder(4 weeks)
- Changes in self-reported symptoms of anhedonia from baseline to the end of the 32-week treatment phase(32 weeks)
- Changes in High-sensitivity C-reative protein (hs-CRP) levels from baseline to the end of the 32-week treatment phase(32 weeks)
- Changes in gastrointestinal symptom severity from baseline until the end of the 32-week treatment phase(32 weeks)
研究者
Manish Jha
MBBS, Associate Professor
University of Texas Southwestern Medical Center